Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 5/20 | 0.36 |
| ▸ | VEGFA | P15692 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562173 | 0.91 | EPAS1 (0.34) | EPAS1VEGFACYP1A2POLBCYP2C19 | |
| SCHEMBL5560864 | 0.89 | CYP1A2 (0.31) | EPAS1CYP1A2POLBCYP2C19 | |
| SCHEMBL5555939 | 0.85 | CYP1A2 (0.32) | EPAS1CYP1A2POLBCYP2C19 | |
| SCHEMBL5561648 | 0.85 | EPAS1 (0.32) | EPAS1CYP1A2POLBCYP2C19 | |
| SCHEMBL5563378 | 0.83 | — | — | |
| SCHEMBL5563381 | 0.83 | — | — | |
| SCHEMBL5555400 | 0.83 | CYP1A2 (0.35) | EPAS1VEGFACYP1A2POLBCYP2C19 | |
| SCHEMBL5555486 | 0.79 | CYP1A2 (0.33) | CYP1A2POLBCYP2C19 | |
| SCHEMBL5560726 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2C19 | |
| SCHEMBL14454017 | 0.79 | MAPT (0.33) | CYP1A2POLBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1597235-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-08-15 | — | — | EP | disclosed |
| US-7241794-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHEPALO ALTO LLC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241794-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHEPALO ALTO LLC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20040192666-A1 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192666-A1 | Nonnucleoside reverse transcriptase inhibitors | POLRMT, RRM2B, RRM2 | EPAS1 3601/4885VEGFA 4261/4885CYP1A2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.